Hi Dud - no idea what it is about.
Maybe this:
.............part of a widespread crackdown in China on healthcare corruption and how patient information is disseminated outside of the country.
Earlier this year, five other Chinese employees in AZ's oncology division were detained as part of an investigation into alleged breaches of data privacy laws. |
Tks Al!
Was rejoicing 300pts+ up, stopped out at 105pts down.
Blickin boats/fishing eh? |
Yep - can I get treatment on the nhs for broad shoulders!
Suet |
Suet
From anyone with "something" |
Yes but where will Labour get the dosh from?
Suet |
Underwritten by the UK government when approved if I remember: |
Above post corrected, numbers were in wrong order. |
A rare long that counts, 234pts and counting! |
i.e., they left their price target unchanged. |
Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' |
Thanks Waldron,
Exciting times on most fronts.
Back in 11726.
Confess, was one of my very long term holdings, thought it had peaked £10ish?
Day trading to doddery trading? |
AstraZeneca plc
77.47 USD −0.46 (0.59%)
Oct 4, 16:00 EDT
77.32 USD 11:10
Open
77.08
High
77.55
Low
76.90
Mkt cap
241.98B
P/E ratio
37.56
Div yield
1.92%
CDP score
A-
52-wk high
87.67
52-wk low
60.48 |
Non-Exec Chairman of the Board.
Buy today 2,000 @ £117.927465 = £235,854.93p |
Downgraded this morning. - leaked yesterday ?
Deutsche Bank cuts AstraZeneca to 'sell' (hold) - price target 10,500 (11,000) pence |
Chart support around 11000p hopefully |
Uncertainty about whether their cancer drug will be approved |
China weighing on the share price maybe ? |
On Wednesday, BMO Capital maintained a positive outlook on shares of AstraZeneca (NASDAQ:AZN) shares, reiterating an Outperform rating and a price target of $89.00. The firm's stance comes in the wake of AstraZeneca's investor event, which took place yesterday, following the company's presentations at the World Lung Conference.
Erste Group analyst Hans Engel upgraded AstraZeneca to Buy from Hold citing strong sales growth for the company’s oncology products. AstraZeneca’s operating margin and sales growth are above the sector average and its operating margin shows an upward trend, the analyst tells investors in a research note. The firm says the company’s profits will grow at an above-average rate this year and also in 2025. |
Maybe time to top up?
Long term, maybe a wise move? |
"Astra faces a Chinese burn as Beijing puts Soirot to the test, says ALEX BRUMMER"
Daily Mail |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
